November 21, 2016 - By Hazel Jackson · 0 Comments
The stock of Intersect Ent Incorporated (NASDAQ:XENT) registered an increase of 0.75% in short interest. XENT’s total short interest was 2.07M shares in November as published by FINRA. Its up 0.75% from 2.05 million shares, reported previously. With 171,400 shares average volume, it will take short sellers 12 days to cover their XENT’s short positions. The short interest to Intersect Ent Incorporated’s float is 9.64%. The stock decreased 0.84% or $0.1 during the last trading session, hitting $11.85. About 192,697 shares traded hands. Intersect ENT Inc (NASDAQ:XENT) has declined 37.79% since April 19, 2016 and is downtrending. It has underperformed by 41.65% the S&P500.
Intersect ENT, Inc. is a commercial stage drug-device company. The company has a market cap of $342.80 million. The Firm develops drugs for patients with ear, nose and throat conditions. It currently has negative earnings. It has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents.
Out of 7 analysts covering Intersect ENT (NASDAQ:XENT), 5 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 71% are positive. Intersect ENT has been the topic of 8 analyst reports since August 17, 2015 according to StockzIntelligence Inc. The rating was initiated by Deutsche Bank with “Hold” on Thursday, October 6. The stock of Intersect ENT Inc (NASDAQ:XENT) earned “Overweight” rating by Piper Jaffray on Tuesday, September 29. Canaccord Genuity maintained Intersect ENT Inc (NASDAQ:XENT) on Monday, August 17 with “Buy” rating. Northland Capital initiated Intersect ENT Inc (NASDAQ:XENT) on Tuesday, March 29 with “Outperform” rating. JP Morgan downgraded Intersect ENT Inc (NASDAQ:XENT) on Wednesday, November 2 to “Neutral” rating. The rating was initiated by Bank of America with “Buy” on Friday, December 18. Canaccord Genuity maintained the shares of XENT in a report on Thursday, October 1 with “Buy” rating.
Intersect ENT, Inc., incorporated on October 6, 2003, is a commercial stage drug-device company. The Firm develops drugs for patients with ear, nose and throat (ENT) conditions. The Firm has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company’s commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis.
More recent Intersect ENT Inc (NASDAQ:XENT) news were published by: Fool.com which released: “Here’s Why Intersect ENT, Inc.’s Stock Cratered Today” on November 05, 2015. Also Equitiesfocus.com published the news titled: “Intersect ENT, Inc. (NASDAQ:XENT) Quarterly EPS From Continuing Operations …” on November 21, 2016. Fool.com‘s news article titled: “Why Intersect ENT Shares Are Crashing 31.6% Today” with publication date: May 06, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Hazel Jackson